Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

Bullboard Posts

Comment by moneystarvedon Feb 26, 2014 11:07am

211 Views

Post# 22253221

RE:Zacks initiates research coverage with an outperform

I wish there was a way to make actually useful posts "sticky". Just reposting link to keep it near the top for those coming to check out this stock (one of the top volume stocks on the tsx should attract even more attention). All the info you need is in this report:
https://scr.zacks.com/files/doc_coverage/Biotech%20-%20Jason%20Napodano/ICOTF/February%2025%202014_ICOTF_Napodano.pdf

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity